Full results of Tesaro Inc.'s phase III NOVA trial presented at the European Society for Medical Oncology meeting show that the company's once-daily PARP inhibitor, niraparib, significantly extended the time during which women with recurrent ovarian cancer were able to live with their disease before their tumors began to grow again.